THE NEW GATEKEEPERS

This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.

Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.

The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.

The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.

The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.

A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.

With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.

Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.